AACR-Bayer Clinical Oncology Research (CORE) Training Fellowships
The AACR-Bayer Clinical Oncology Research (CORE) Training Fellowship program is designed to encourage exceptional clinical research by bridging close collaboration between academia and industry. Selected clinical researchers will be provided with real-world experience in clinical development at a Bayer facility in Cambridge, Massachusetts.
During the research year at Bayer, Dr. Ravi will be paired with a Bayer scientist who will serve as his mentor, and he will shadow the mentor on their various activities, including meetings with project and study teams. This includes discussions on various topics (e.g., drug development strategy and execution, regulatory strategy implementation, statistics, marketing, clinical operations) with key stakeholders. Research conducted during this year will provide Dr. Ravi with the opportunity to gain experience in drug development and understand challenges in early-stage and late-stage clinical research. Additional focus areas may also be provided (e.g., preclinical research, biomarker discovery).
Dr. Ravi received his medical degree at the University of Cambridge and obtained his MRCP in London before completing a residency in internal medicine at the Mayo Clinic. He then completed a fellowship in medical oncology at Dana-Farber Cancer Institute, and recently became an instructor of medicine at the Lank Center for Genitourinary Oncology at Dana-Farber and Harvard Medical School. He treats patients and performs clinical research in genitourinary cancers and is interested in conducting clinical trials and identifying biomarkers that may ultimately enable personalization of cancer therapy to each patient.
Acknowledgment of Support
I am delighted and honored to receive the AACR-Bayer CORE Training Fellowship. This will provide dedicated time and funding for me to pursue further training in drug development and clinical trial design and will therefore be invaluable to my overall career development as a clinical investigator in genitourinary cancers.